Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and...

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• The tumor microenvironment often suppresses immune responses, limiting the efficacy of cancer vaccines.
• Immune checkpoints, such as PD-1 and CTLA-4, play a critical role in regulating T cell activity and maintaining self-tolerance.

Purpose of the Study:

• To evaluate the synergistic anti-tumor effects of an antigen-specific DNA vaccine combined with PD-1 or CTLA-4 blockade.
• To elucidate the underlying mechanisms by which this combination therapy enhances anti-tumor immunity.

Main Methods:

• Utilized a syngeneic mouse tumor model expressing HPV16 E6/E7 antigens.
• Administered an E7-specific DNA vaccine in combination with anti-PD-1 or anti-CTLA-4 antibodies.
• Assessed immune responses, including antibody production, cytotoxic T lymphocyte activity, regulatory T cell populations, and dendritic cell function.

Main Results:

• The combination of DNA vaccine with anti-PD-1 or anti-CTLA-4 blockade significantly augmented antigen-specific immunity (anti-E7 antibodies, CD8+ T cell number, and cytotoxicity).
• This combination therapy led to a reduction in both systemic and intratumoral regulatory T cells (Tregs).
• Enhanced maturation and antigen-presenting capabilities of intratumoral dendritic cells (DCs) were observed, facilitating T cell activation.

Conclusions:

• Immune checkpoint blockade effectively overcomes the immunosuppressive tumor microenvironment, potentiating the effects of antigen-specific DNA vaccines.
• The combination of antigen-specific immunotherapy with immune checkpoint inhibitors represents a promising novel strategy for clinical cancer therapy.